MSD is Looking for a Digital Health Solution to Empower Oncologists by Keeping them Updated in their Field

MSD Lebanon is looking for an external partner to co-create a digital solution that helps oncologists to stay updated with relevant clinical content about cancer. The solution should consider several channels (web, app, email newsletter, social media, etc) and adapt to the preferences to each user, so they are motivated to access the content regularly over time.

As a leading pharmaceutical company, MSD is aware of the need to incorporate open Innovation for better healthcare. The best ideas may not always pop up where challenges are identified. That is why MSD wants to support and partner with external talent to collaboratively develop competitive solutions following a win-win approach.

The Lebanon-College Challenge: Empowering oncologists to save lives

Lebanese oncologists face challenges to stay updated with their practice, mainly due to time constraints. The vast amount of data that is being published in the field, and their clinical and academic responsibilities, are the main reasons for these time limitations.

MSD Lebanon aims to enter into a co-creation process with an external partner that provides the service that includes the use of a digital solution that helps oncologists to stay updated with relevant clinical content about cancer updates. The applicant must be able to provide both the content and the technological platform to deliver it to the Lebanese doctors.

Expected functionality and characteristics: The applicant must be able to manage the whole life-cycle of the content - identification, selection, tagging, uploading. Besides, the digital solution must be: user-friendly, trustable, multi-channel, multi-content, customizable, adherent, measurable, restricted to Lebanese oncologists, provide printed copies of content, comply with security and privacy.

The schedule

The process is done in five steps:
1. Solutions submitted before 21st December 2018 are reviewed by the MSD team.
2. Up to four finalists will be announced on 21st January 2019.
3. Finalists receive mentorship to improve their initial proposal.
4. Finalists pitch their proposal at the Selection Event in Beirut on 5th March 2019.
5. Winning proposal will be co-created and rolled-out in the local market with MSD team support.

The prizes

The winner will receive the following:
  • Up to $20,000 to pilot their solution in the challenge-related local market (Lebanon).
  • Support from MSD local team to connect with the local ecosystem (eg. medical professional associations), deal with potential regulatory issues and disseminate leveraging MSD local channels. It will also contribute with expertise and business know-how.
  • If the launch is a success after 12 months, its outcomes will be globally shared within MSD to investigate further implementation beyond the initial market.

Each finalist will receive €400 to cover travel expenses. It is compulsory to physically attend the event to become a winner (no remote presentations).

Who can apply? Any company that is incorporated in any country. Consortia are permitted. Any technology is welcome with the exception of chatbots. The working language will be English.

For detailed information about the initiative including challenges and process, please visit:
http://www.msdinnovationfactory.com

About the MSD Innovation Factory and MEA Region

Since 2016 the MSD Innovation Factory has been established as an open innovation vehicle for the MEA Region with the main objective of finding co-creation opportunities with external partners to deliver sustainable solutions for our patients and customers.

With a footprint that spans across 2 continents and serving a population of close to 1.7 billion people, MEA is one of the most diverse regions within MSD. Our region is a true melting pot, possessing a rich mix of cultures, ethnicities and backgrounds that are fundamental to our company's success. As we aspire to improve health and wellness across MEA, we apply the combined knowledge, skills and experiences of thousands of employees in the Human Health, Animal Health, Manufacturing and Research divisions.

Our researchers are at the forefront of exploring new ways to address health challenges, with clinical trials running in several countries across the region. High disease burdens across the region for Cancer, Hepatitis C and Diabetes among many others, keep us conscious of our responsibility, and committed to our mission to ensure that the medicines and vaccines we invent will lead to better health for society for generations to come.

Most Popular Now

Merck and Tencent Announce Collaboration…

Merck, a leading science and technology company, signed a strategic collaboration agreement with Tencent, a leading provider of Internet value added services. The collaboration will primarily focus on increasing public...

Merck Granted U.S. Patent for Novel Comb…

Merck, a leading science and technology company, today announced that it has been granted Patent No. US 10,193,695 by the United States Patent and Trademark Office (USPTO). The patent relates...

The European Health Catapult Program for…

Through dedicated sessions, a group of international top-level investors, key healthcare leaders and industry stakeholders work closely together challenging 40+ ambitious startups to optimize their business plan and strengthen their...

Applications Now Open for Pioneering Dig…

The Yorkshire & Humber AHSN (Academic Health Science Network), in partnership with mHabitat, announces that applications for the 2019 Propel@YH digital health accelerator programme are now open. Propel@YH has been...

Flagship Axe the Fax Trust Rolls out Hyb…

Leeds Teaching Hospitals NHS Trust (LTHT), the organisation at the forefront of the national Axe the Fax campaign, is implementing an electronic fax solution to tackle its last remaining machines...

First EU Citizens Using ePrescriptions i…

The first EU patients can use digital prescriptions issued by their home doctor when visiting a pharmacy in another EU country: Finnish patients are now able to go to a...

Boehringer Ingelheim (Canada) Ltd. and I…

Boehringer Ingelheim (Canada) Ltd. and IBM Canada announced at the Healthcare Information and Management Systems Society (HIMSS) conference in Orlando, Florida, their plans to explore the use of blockchain technology...

Final Report: Provision of a Market Stud…

The aim of the study is to examine the telemedicine market in Europe and to understand the factors that determine its development. The analysis maps telemedicine applications and solutions, and...

Open Access Drug Development Tools Featu…

New open access tools for drug development, obesity, and the environmental impacts of medicines are the focus of a new IMI2 Call for proposals launched today. The total budget of...

The NHS Long Term Plan: Cracking the Da …

Opinion Article by Prof. Michael Thick, Chief Medical Officer, Chief Clinical Information Officer, IMS MAXIMS Reading the NHS Long Term Plan this week, I had a definite sense of déjà vu...

Big Data Approach Shown to be Effective …

Researchers at Rensselaer Polytechnic Institute who developed a blood test to help diagnose autism spectrum disorder have now successfully applied their distinctive big data-based approach to evaluating possible treatments. The...

Highland Marketing Advisory Board Respon…

The first meeting of Highland Marketing's newly expanded advisory board discussed the NHS Long Term Plan and what will be needed to make it a success. Structural change, leadership, investment...